You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康宁杰瑞制药(09966.HK)将呈列两种双特异性抗体之研究结果
阿思达克 05-20 08:49
康宁杰瑞制药-B(09966.HK)公布,将於2021年美国临床肿瘤学会年会呈列KN046(一种重组人源化PD-L1/CTLA-4双特异性抗体)及KN026(一种基於Fc的抗HER2双特异性抗体)的研究结果,美国临床肿瘤学会为医生及肿瘤学专业人士关爱癌症患者的世界领先专业机构。

KN046的临床前及临床试验结果展现出良好的有效性,并表明KN046有望降低脱靶毒性。KN046旨在被开发为突破性肿瘤免疫特效药。KN026正在中国进行数项I/II期临床试验,并正在美国进行一项I期临床试验。KN026已在晚期HER2+乳腺癌及GC/GEJ 患者中表现出良好的初步疗效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account